AnaptysBio filed a motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court regarding their Collaboration Agreement over royalties from Jemperli (dostarlimab). Anaptys claims it sought good faith discussions to resolve alleged breaches by Tesaro and GSK, but Tesaro initiated a lawsuit without notice. The court is expected to hear arguments by early March, with trial scheduled for July 14-17, 2026.

GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.

AnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.

Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.

The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.

AnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.

AnaptysBio, a clinical-stage biotechnology company, announced the pricing of a $100 million underwritten offering of its common stock. The offering was led by existing investor EcoR1 Capital and included participation from new and existing investors, including Sanofi.

Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Nierengarten Wedbush Maintains Outperform $34.00 - David Risinger Leerink Partners Announces Outperform $47.00 - Derek Archila Wells Fargo Announces Overweight $56.00 - Anupam Rama JP Morgan Lowers Neutral $28.00 $30.00 Julian Harrison BTIG Announces Buy $55.00 - Alex Schwartz Stifel Announces Buy $50.00 - Yasmeen Rahimi Piper Sandler Announces Overweight $80.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of ...Full story available on Benzinga.com

AnaptysBio (ANAB) delivered earnings and revenue surprises of -6.49% and 57.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.